-
1
Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies
Published 2024-12-01Subjects: “…Anti-PD-1/PD-L1…”
Get full text
Article -
2
Discovery of novel biphenyl compounds bearing hydroxamic acid moiety as the first PD-L1/class I HDACs dual inhibitors
Published 2025-12-01Subjects: “…PD-1/PD-L1…”
Get full text
Article -
3
Inosine enhances the efficacy of immune‐checkpoint inhibitors in advanced solid tumors: A randomized, controlled, Phase 2 study
Published 2024-09-01Subjects: Get full text
Article -
4
Extraction, GC-MS analysis, cytotoxic, anti-inflammatory and anticancer potential of Cannabis sativa female flower; in vitro, in vivo and in silico
Published 2025-02-01Subjects: Get full text
Article -
5
Periodontitis promotes tumor growth and immune evasion via PD-1/PD-L1
Published 2024-11-01Subjects: Get full text
Article -
6
Progression patterns in patients with advanced hepatocellular carcinoma treated with local therapy, targeted drugs, and PD-1/PD-L1 inhibitors
Published 2024-08-01Subjects: Get full text
Article -
7
-
8
Immune-related adverse events with PD-1/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients
Published 2025-01-01Subjects: “…PD-1/PD-L1 inhibitors…”
Get full text
Article -
9
Illuminating the impact of CD38-induced adenosine formation in B-cell lymphoma
Published 2025-01-01Subjects: Get full text
Article